Skip to main content

Fiscal Wizard · Single-issue tearsheet

TRAW / Jun 21, 2026 Run #7277

TRAW

Traws Pharma, Inc.

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Composite verdict

D 31.5 / 100
Bearish setup · Trend Following 12 drivers · 7 gates blocking
  • Elder Force Index
  • Keltner Channels
  • Relative Strength vs SPY
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 162nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 14 signals100% Bear
Momentum Bearish 0Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Above average

63.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
OCF to Net Income 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Earnings Yield 100
Cash Conversion 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Elder Force Index, Keltner Channels, Relative Strength vs SPY); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Elder Force Index 16
Aroon Oscillator 17
Chaikin Money Flow 18

Risk Gates

7 blocking 2 caution

7 guards active, 25 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TRAW.